Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Karl J. Aichberger, Matthias Mayerhofer, Karoline V. Gleixner, Maria-Theresa Krauth, Alexander Gruze, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Leonhard Müllauer, Hermine Agis, Christian Sillaber, Peter Valent

Blood (2006) 109 (7): 3031–3041.

https://doi.org/10.1182/blood-2006-07-032714

Published: 2006

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

Journal Articles

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

Alexander W. Hauswirth, MD, Stefan FLorian, MD, Maria-Theresa Krauth, MD, Gerit-Holger Schernthaner, MD, Edgar Selzer, MD, Volker Wacheck, MD, Dieter Printz, Gerhard Fritsch, MD, Karl Sotlar, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2005) 106 (11): 4324.

https://doi.org/10.1182/blood.V106.11.4324.4324

Published: 2005

Journal Articles

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Hermine Agis, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 3516.

https://doi.org/10.1182/blood.V106.11.3516.3516

Published: 2005

Journal Articles

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Karl J. Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, Hans Skvara, Stefan Florian, Karoline Sonneck, Cahit Akgul, Sophia Derdak, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Brett P. Monia, Richard Moriggl, Peter Valent, Christian Sillaber

Blood (2005) 105 (8): 3303–3311.

https://doi.org/10.1182/blood-2004-02-0749

Published: 2005

Journal Articles

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Hans Skvara, MD, Stefan Florian, MD, Karoline Sonneck, MD, Cahit Akgul, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Brett P. Monia, PhD, Richard Moriggl, PhD, Peter Valent, MD, Christian Sillaber, MD

Blood (2004) 104 (11): 2972.

https://doi.org/10.1182/blood.V104.11.2972.2972

Published: 2004

NARROW

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Email alerts

ASH Publications

American Society of Hematology

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only